Loading
Modular Medical, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 24 Mar 2025.
Modular Medical, Inc.: what insiders have been doing
Modular Medical, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Over the twelve months to 18 October 2026, the company's managers filed 11 filings, from 4 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Over the last twelve months, not one insider purchase of Modular Medical, Inc. stock was filed. The median gap between a trade and its publication by SEC (Form 4) is 5 days. For comparison, the SEC allows two business days to file a Form 4.
Compared with its exchange (5,812 companies, median 19 filings), a count of 11 filings is below the norm. Over the whole record (from 2021), the tally stands at 18 purchases and no sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
103
Thresholds
n/a
Buy Volume
€4M
18 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleManchester Management Co LLC4 buys
Since the insiders bought
- -83.6%Entry US$34.20 · Close at T+365 US$5.61
- -52.6%Entry US$114.00 · Close at T+365 US$54.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2026FY ended March 2026 · cache
US$1.95
Analyst consensus
Income statement
EBITDA-US$25.9M
Net income-US$28.2M0.0% margin
Valuation
P/Book1.0x
Beta0.30
Balance sheet & cash
Market capUS$18.5M
Total debtUS$393k
Free Cash Flow-US$27.7M
Debt / Equity3%
Profitability & ownership
ROE-247.9%
ROA-129.1%
% insiders1.5%
% institutions24.1%
Last declaration on 1 October 2026
Declarations103 total
25 sharesCommon StockSEC:0001213900-26-105971:0
83 sharesCommon stockSEC:0001213900-26-105963:0
108 sharesCommon StockSEC:0001213900-26-105960:0
25 sharesCommon StockSEC:0001213900-26-041557:0
83 sharesCommon stockSEC:0001213900-26-041555:0
103 sharesCommon StockSEC:0001213900-26-041554:0
3,125 sharesCommon StockSEC:0001213900-26-001366:0
2,500 sharesCommon stockSEC:0001213900-26-001375:0
750 sharesCommon StockSEC:0001213900-26-001367:0
60,000 sharesCommon StockSEC:0001213900-25-121715:0
22,000 sharesCommon StockSEC:0001213900-25-121713:0
750 sharesCommon StockSEC:0001213900-25-095749:0
2,500 sharesCommon stockSEC:0001213900-25-095747:0
3,125 sharesCommon StockSEC:0001213900-25-095744:0
2,500 sharesCommon stockSEC:0001213900-25-060672:0
3,125 sharesCommon StockSEC:0001213900-25-060671:0
750 sharesCommon StockSEC:0001213900-25-060669:0
625 shares@ US$1.1043.2% of flowCommon StockSEC:0001213900-25-027223:0
750 shares@ US$1.1043.2% of flowCommon StockSEC:0001213900-25-027222:0
2,500 sharesCommon stockSEC:0001213900-25-027219:0
2,500 sharesCommon stockSEC:0001213900-25-027220:0
520,832 shares@ US$1.9223.8% of flowCommon Stock, par value $0.001 per shareSEC:0000919574-25-002089:0
Canonical exit: 18 Jun 2025 (T+90)
9,374 sharesCommon StockSEC:0001013762-25-001763:0
62,500 sharesCommon StockSEC:0001013762-25-001764:0
625 shares@ US$1.3956.8% of flowCommon StockSEC:0001213900-25-000733:0
25 of 103 declarations
About Modular Medical, Inc.
Modular Medical, Inc. (NASDAQ: MODD) is a United States-based medical device company headquartered in San Diego, California. For French, Belgian, and Swiss investors, it is best viewed as a micro-cap diabetes-care developer with a focused equity story: simplifying insulin delivery and lowering the barriers to pump adoption for adult patients. The company was founded by Paul DiPerna, a microfluidics engineer and long-time medical device operator who also played a role in the creation of Tandem Diabetes Care. Modular Medical’s roots date back to 2015, and the business later became a public company through a financed shell transaction in 2017, which helps explain its entrepreneurial profile and its still-developing commercial base.
The company’s core activity is the design, development, and eventual commercialization of next-generation insulin pump technologies. Its lead product is MODD1, a two-part patch pump intended to be easier to learn, easier to use, and potentially more affordable than some existing alternatives. Modular Medical also references its Pivot platform, which is aligned with the same strategic objective: making insulin delivery less complex and more accessible. At this stage, the company remains a development-stage medical device business rather than a scaled commercial player. As such, the investment case is driven by innovation, regulatory progress, manufacturability, and commercial readiness.
Read moreShow less
Competitively, Modular Medical operates in a diabetes-device market dominated by much larger incumbents with established manufacturing scale, payer relationships, and field sales infrastructure. MODD’s differentiation is not size, but product positioning. The company is targeting adult users who are interested in pump therapy but have historically been discouraged by cost, complexity, or usability concerns. That “accessibility” angle is strategically attractive, but it also means execution risk remains significant, particularly around regulatory timelines, production readiness, and market adoption.
Geographically, the business is overwhelmingly U.S.-centric today, with its headquarters and operating base in San Diego, California. Recent disclosures also indicate an intention to pursue foreign regulatory clearance for Pivot, suggesting a longer-term ambition beyond the domestic market, though the near-term focus remains the United States. From a listing perspective, Modular Medical trades on the NASDAQ Capital Market under the ticker MODD, which is important context for investors assessing liquidity and volatility.
Recent developments have been centered on capital raising and product advancement. In 2025 and 2026, the company completed or announced multiple equity financings, underscoring the cash-intensive nature of a pre-revenue medtech platform. In 2024, MODD1 received FDA clearance for adult use, a meaningful milestone that validates the product concept and regulatory pathway. However, the company is still working through commercialization preparation, manufacturing improvement, and broader product development. In practical terms, Modular Medical remains a story of optionality: a differentiated diabetes platform with a compelling unmet-need narrative, but one that still must convert regulatory progress into sustainable commercial traction.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
